Actively Recruiting
Evaluation of Oral Anti-malarial Drug Combinations Versus Standard Care in Children With Uncomplicated Plasmodium Falciparum Malaria
Led by Novartis Pharmaceuticals · Updated on 2026-10-15
120
Participants Needed
13
Research Sites
2 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of a combination of anti-malarial drugs in children aged 2 to under 12 years with uncomplicated Plasmodium falciparum malaria. This phase 2 platform study compares a single oral dose of up to three anti-malarial agents given together to the standard treatment known as Coartem. The study aims to better understand how these treatments work and their safety profiles in this young population. Participants are randomly assigned to one of two groups one receiving an oral combination of KLU156 with KAE609 alongside a light meal, and the other receiving the standard of care, Artemether plus lumefantrine, given orally according to the usual guidelines. This open-label, two-arm study monitors each treatment groups response to therapy. Throughout the study, participants undergo evaluations including parasite clearance times and blood tests to measure drug levels over the first week, with the main outcome assessed on day 29 using PCR to confirm clinical and parasitological response. Safety and tolerability are also closely monitored, and the total duration of participation extends up to 29 days after treatment initiation to assess treatment outcomes comprehensively.
CONDITIONS
Brief Title
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here